Up to now, there have been 2 types of anti-hepatitis B virus drugs approved in China, interferon, and 5 types of nucleoside (acid) analogues for oral administration. Interferons are divided into regular interferons and long-acting interferons. There are 2 types of long-acting interferons, Pyroxin, which was used earlier in hepatitis B, and Pellegrin, which was only approved in 2007 for the treatment of slow-onset hepatitis B. Nucleoside (acid) analogs include lamivudine, adefovir, entecavir, tipifudine and tenofovir. Other than these, there are no other drugs that are approved to fight the hepatitis B virus, so patients should not resort to hearsay. What are the advantages and disadvantages of each class of antiviral drugs: Nucleoside (acid) analogs have a direct inhibitory effect on viral replication, while interferon also has a direct antiviral effect, but is mainly an immunomodulatory agent, so each class of drugs has its own characteristics. The nucleoside (acid) analogs have a stronger role in inhibiting viral replication and faster symptom control; interferon has a higher chance of converting “major triplets” to “minor triplets” and is effective with stable efficacy and fewer relapses. In terms of disadvantages, nucleoside (acid) analogs require long-term treatment and are prone to relapse after discontinuation, while long-term treatment has drug resistance problems; interferon does not have drug resistance problems and the course of treatment is relatively limited, but the injectable form is relatively inconvenient to use and has more adverse effects, such as local injection pain, fever, headache and other flu-like symptoms.